Cite
Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation.
MLA
Xu, Hanchen, et al. “Atractylenolide I Enhances Responsiveness to Immune Checkpoint Blockade Therapy by Activating Tumor Antigen Presentation.” The Journal of Clinical Investigation, vol. 131, no. 10, May 2021. EBSCOhost, https://doi.org/10.1172/JCI146832.
APA
Xu, H., Van der Jeught, K., Zhou, Z., Zhang, L., Yu, T., Sun, Y., Li, Y., Wan, C., So, K. M., Liu, D., Frieden, M., Fang, Y., Mosley, A. L., He, X., Zhang, X., Sandusky, G. E., Liu, Y., Meroueh, S. O., Zhang, C., … Lu, X. (2021). Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation. The Journal of Clinical Investigation, 131(10). https://doi.org/10.1172/JCI146832
Chicago
Xu, Hanchen, Kevin Van der Jeught, Zhuolong Zhou, Lu Zhang, Tao Yu, Yifan Sun, Yujing Li, et al. 2021. “Atractylenolide I Enhances Responsiveness to Immune Checkpoint Blockade Therapy by Activating Tumor Antigen Presentation.” The Journal of Clinical Investigation 131 (10). doi:10.1172/JCI146832.